ImmuONE announces launch of first product ImmuPHAGE™ to understand the safety of inhaled substances in vitro

“Laboratories across the world are recognising the need for more accurate and sustainable ways to evaluate immune reactions in the lung, and I’m proud that we are able to provide a new answer to that today,” said Dr Abigail Martin, co-founder and CEO of ImmuONE. “It is a testament to our ongoing mission to find better ways to determine chemical safety or toxicity in human lungs.” 

The ImmuPHAGE™ model is composed of alveolar-like macrophage cells assembled in vitro on tissue well plates. These cells closely represent the form and function of human cells. Companies and researchers can then add their target substance to the well plates to evaluate how the cells react.  

This can provide researchers with detailed information about how chemical and biochemical products may irritate the lungs. This is an important advantage over other methods, which only give an “alive” or “dead” result.  

For example, ImmuPHAGE™ has applications in evaluating inhalation toxicology, cytotoxicity screening, and monitoring macrophage uptake. This is useful for clients in a range of sectors, including cosmetics, tobacco, fragrances, agri-chemicals, pharmaceuticals, and academic researchers who want to know more about human lung responses. 

In some cases, ImmuPHAGE™ can dramatically reduce or even eliminate the need for animal testing, helping laboratories to achieve their responsible research goals. 

ImmuPHAGE™ is fully validated and characterised for cell structure & viability, phagocytic activity and cytokine response.